UBS AM
CODX

UBS AM’s Co-Diagnostics CODX Stock Holding History

UBS AM’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-837
Closed -$239K – 2761
2021
Q1 		$239K Hold
837
– – ﹤0.01% 2534
2020
Q4 		$233K Buy
837
+447
+115% +$166K ﹤0.01% 2471
2020
Q3 		$159K Hold
390
– – ﹤0.01% 2429
2020
Q2 		$226K Buy
+390
New +$178K ﹤0.01% 2353

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS AM's CODX Position: Q2 2021 in Review

UBS AM sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 837 shares — an estimated $239K sold.

UBS AM first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $239K in Q1 2021. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • UBS AM reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • UBS AM sold 837 Co-Diagnostics shares in Q2 2021, an estimated $239K.
  • UBS AM first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • UBS AM's Co-Diagnostics position peaked at $239K in Q1 2021.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.